• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与抗纤维蛋白单克隆抗体结合可增强组织型纤溶酶原激活剂在体外的纤溶活性。

Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.

作者信息

Runge M S, Bode C, Matsueda G R, Haber E

机构信息

Massachusetts General Hospital, Boston.

出版信息

Biochemistry. 1988 Feb 23;27(4):1153-7. doi: 10.1021/bi00404a012.

DOI:10.1021/bi00404a012
PMID:3130094
Abstract

Tissue plasminogen activator (tPA) was covalently linked by disulfide bonds to a monoclonal antibody specific for the amino terminus of the beta chain of fibrin (antibody 59D8). The activity of the tPA-59D8 conjugate was compared with that of tPA, urokinase (UK), and a UK-59D8 conjugate. For lysis of fibrin monomer, tPA was 10 times as potent as UK, whereas both UK-59D8 and tPA-59D8 conjugates were 100 times as potent as UK and 10 times as potent as tPA. Conjugation of tPA or UK to antibody 59D8 produced a 3.2-4.5-fold enhancement in clot lysis in human plasma over that of the respective unconjugated plasminogen activator. However, the UK-59D8 conjugate was only as potent as tPA alone. Antibody-conjugated tPA or UK consumed less fibrinogen, alpha 2-antiplasmin, and plasminogen than did the unconjugated activators, at equipotent fibrinolytic concentrations. Antibody targeting thus appears to increase the concentration of tPA in the vicinity of a fibrin deposit, which thereby leads to enhanced fibrinolysis.

摘要

组织型纤溶酶原激活剂(tPA)通过二硫键与针对纤维蛋白β链氨基末端的单克隆抗体(抗体59D8)共价连接。将tPA - 59D8偶联物的活性与tPA、尿激酶(UK)和UK - 59D8偶联物的活性进行了比较。对于纤维蛋白单体的溶解,tPA的效力是UK的10倍,而UK - 59D8和tPA - 59D8偶联物的效力都是UK的100倍,是tPA的10倍。将tPA或UK与抗体59D8偶联,在人血浆中产生的凝块溶解作用比各自未偶联的纤溶酶原激活剂增强了3.2 - 4.5倍。然而,UK - 59D8偶联物的效力仅与单独的tPA相当。在等效的纤维蛋白溶解浓度下,抗体偶联的tPA或UK比未偶联的激活剂消耗的纤维蛋白原、α2 - 抗纤溶酶和纤溶酶原更少。因此,抗体靶向似乎增加了纤维蛋白沉积物附近tPA的浓度,从而导致纤维蛋白溶解增强。

相似文献

1
Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.与抗纤维蛋白单克隆抗体结合可增强组织型纤溶酶原激活剂在体外的纤溶活性。
Biochemistry. 1988 Feb 23;27(4):1153-7. doi: 10.1021/bi00404a012.
2
Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.抗体增强溶栓作用:组织纤溶酶原激活剂在体内的靶向作用
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7659-62. doi: 10.1073/pnas.84.21.7659.
3
Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.与抗纤维蛋白Fab'结合可增强单链尿激酶型纤溶酶原激活剂的纤溶活性。
Circulation. 1990 Jun;81(6):1974-80. doi: 10.1161/01.cir.81.6.1974.
4
Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.抗体导向纤维蛋白溶解。一种对纤维蛋白和组织纤溶酶原激活物均具有特异性的抗体。
J Biol Chem. 1989 Jan 15;264(2):944-8.
5
Hybrid molecules: insights into plasminogen activator function.杂合分子:对纤溶酶原激活物功能的见解
Mol Biol Med. 1991 Apr;8(2):245-55.
6
Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
Thromb Haemost. 1990 Oct 22;64(2):260-6.
7
Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.对纤维蛋白和纤溶酶原激活剂具有反应性的双特异性单克隆抗体对纤维蛋白溶解的增强作用。
Thromb Res Suppl. 1990;10:83-9. doi: 10.1016/0049-3848(90)90382-m.
8
Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.一种由抗纤维蛋白单链抗体和低分子量尿激酶组成的重组纤溶酶原激活剂的构建与表征
J Thromb Haemost. 2004 May;2(5):797-803. doi: 10.1111/j.1538-7836.2004.00697.x.
9
Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.一种抗体-尿激酶偶联物的特性。一种靶向纤维蛋白的纤溶酶原激活剂。
J Biol Chem. 1987 Aug 5;262(22):10819-23.
10
A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.双特异性抗体增强单链尿激酶的纤溶活性。
Biochemistry. 1990 Jul 10;29(27):6374-8. doi: 10.1021/bi00479a005.

引用本文的文献

1
Targeted thrombolysis by magnetoacoustic particles in photothrombotic stroke model.光血栓性中风模型中磁声颗粒的靶向溶栓作用
Biomater Res. 2022 Oct 22;26(1):58. doi: 10.1186/s40824-022-00298-y.
2
A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.一种新型强效溶栓融合蛋白,由抗不溶性纤维蛋白抗体和突变型尿激酶组成。
Thromb Haemost. 2022 Jan;122(1):57-66. doi: 10.1055/a-1488-3723. Epub 2021 Jun 15.
3
Translational initiatives in thrombolytic therapy.溶栓治疗的转化研究。
Front Med. 2017 Mar;11(1):1-19. doi: 10.1007/s11684-017-0497-8. Epub 2017 Mar 2.
4
Thrombolytic therapy in acute myocardial infarction--selected recent developments.
Ann Hematol. 1994 Oct;69(4):S35-40. doi: 10.1007/BF02215957.
5
Thrombolytic agents in development.正在研发的溶栓剂。
Drugs. 1995 Jul;50(1):29-42. doi: 10.2165/00003495-199550010-00003.
6
New strategies in the development of thrombolytic agents.溶栓药物开发的新策略。
Blut. 1988 Oct;57(4):147-62. doi: 10.1007/BF00319543.
7
Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.纤溶酶原激活剂与纤维蛋白的结合:特性及药理学后果
Biochem J. 1989 Jul 15;261(2):313-24. doi: 10.1042/bj2610313.
8
[Antibody mediated thrombolysis. A new therapeutic principle].
Klin Wochenschr. 1989 Jul 3;67(13):651-8. doi: 10.1007/BF01718025.
9
A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.一种对纤维蛋白具有高亲和力的重组嵌合纤溶酶原激活剂在体外和体内均具有增强的溶栓效力。
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10337-41. doi: 10.1073/pnas.88.22.10337.
10
Cardiovascular therapies in the 1990s. An overview.20世纪90年代的心血管治疗。综述。
Drugs. 1991 Mar;41(3):345-57. doi: 10.2165/00003495-199141030-00003.